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Background: Previously we have suggested that cancer cells develop a mechanism(s) which allows for either:
silencing of the wild-type TP53 transcription, degradation of the wild-type TP53 mRNA, or selective overproduction
of the mutated TP53 mRNA, which is the subject of this article. Sequencing of TP53 on the respective cDNA and DNA
templates from tumor samples were found to give discordant results. DNA analysis showed a pattern of heterozygous
mutations, whereas the analysis of cDNA demonstrated the mutated template only. We hypothesized that different
TP53 gene expression levels of each allele may be caused by the polymorphism within intron 3 (PIN3). The aim of this
study was to test if one of the polymorphic variants of PIN3 (A1 or A2) in the heterozygotes is associated with a higher
TP53 expression, and therefore, responsible for the haploinsufficiency phenomenon.
Methods: 250 tumor samples were tested. To analyze the involvement of PIN3 polymorphic variant (A1 or A2) on TP53
mRNA expression regulation, bacterial subcloning combined with sequencing analyses, dual luciferase reporter assays
and bioinformatic analysis were performed.
Results: Haplotype analysis showed the predominance of the mutated template during the cDNA sequencing in all
samples showing a heterozygous TP53 mutation and PIN3 heterozygosity. Out of 30 samples (from the total of 250
tested samples) which carried TP53 mutations and had a bias in allelic expression 6 were heterozygous for the A1/A2
polymorphism, and all 6 (p = 0.04) samples carried the mutation within the PIN3 longer allele (A2). Reporter assays
revealed higher luciferase activity in cells transfected with the plasmid containing A2 construct than A1 and control.
A2/A1 ratio ranged from 1.16 for AD293 cell line (p = 0.019) to 1.59 for SW962 cell line (p = 0.0019). Moreover,
bioinformatic analyses showed that PIN3 duplication stabilized secondary DNA structures – G-quadruplexes.
Conclusion: TP53 alleles are not equivalent for their impact on the regulation of expression of TP53 mRNA. Therefore,
in PIN3-heterozygous cases a single TP53 mutation of the longer allele might sufficiently destabilize its function.
Secondary DNA structures such as quadruplexes can also play a role in PIN3-dependent TP53 haploinsufficiency.
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TP53 is one of the most prominent suppressor proteins
and the respective gene is the most thoroughly studied
one. Typically, tumor suppressor genes show either homo-
or hemizygous mutations, but TP53 is an exception in this
aspect [1]. We have already suggested that the dominant
negative effect and gain of function are supported by an* Correspondence: marta.winiecka@gmail.com
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article, unless otherwise stated.unknown mechanism causing higher expression of the
mutated allele (in comparison to the normal allele) in cells
with a heterozygous mutation [2]. Here, we made a further
insight into the influence of PIN3 polymorphism on the
regulation of TP53 expression.
We have already reported the differences in the results
of sequencing of the TP53 gene between the analyses
performed on DNA and those performed on the respect-
ive cDNA [3]. The former presented the heterozygous
pattern, whereas the latter demonstrated the mutated
template only. This observation was an incentive to thed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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We hypothesized that the differences in the expression
levels between alleles may be an effect of polymorphisms
or epigenetic changes.
Albeit relatively infrequent, TP53 polymorphisms may
be important from the perspective of susceptibility to
various cancers. PIN3 and codon 72 polymorphisms are
the two most frequently observed. Codon 72 polymorph-
ism, leading to arginine-proline substitution, and thus,
affecting the structure of the resulting protein [4], occurs
within a proline-rich region, which controls growth sup-
pression and apoptosis [5,6]. It has been reported that
Arg/Arg homozygotes are more efficient in apoptosis
induction than Pro/Pro homozygotes, which, in turn, play
a role in cell cycle arrest in G1 phase [7,8]. Codon 72 poly-
morphism has been reported as associated with breast,
lung and bladder cancer susceptibility [9-11].
Polymorphism in TP53 intron 3 (PIN3) is a 16 bp du-
plication (5’-ACCTGGAGGGCTGGGG-3’). The allele
with only one repetition of 16 bp at the PIN3 site is
usually marked as A1 or N (non-duplicated), the other
(with 2 repetitions) is marked as A2 or D (duplicated).
PIN3 is also responsible for the unique DNA conformer
construction – a G-quadruplex structure, which overlaps
intron 3 [12].
Since PIN3 is related to higher cancer susceptibility
(including breast and colorectal) [13-15], we hypothesized
that the insertion may cause different expression of each
allele. Both exon 3 (22 bp) and intron 3 (93 bp) of the
TP53 gene are relatively short, so an increase of intron 3
length by 17% (16 bp) may even influence the protein
function. As reported by Mergny et al., the primary nu-
cleotide sequence composition of tetramolecular struc-
tures can affect and change melting temperature and
association constant values [16], which influences both
G-quadruplex formation and stability, further affecting
gene expression and protein function [16]. Marcel et al.
described the importance of intronic G-quadruplexes in
the process of TP53 alternative splicing [12]. Formation
of the mentioned structures interferes with the excision
of intron 2, which has an alternative translation start
site, resulting in a Δ40p53 isoform [12], which, when
expressed in excess, exerts a negative effect on the wild-
type protein [17]. Finally, Uhlemann et al. suggested that
not only the regulatory elements, but also the areas be-
tween them affect the gene expression [18]. They reported
that the variation of TA repeats polymorphism upstream
the promoter of the gp91phox results in differences in the
activation of gp91phox promoter [18].
Gemignani et al. reported that the shorter allele (A1)
provides higher expression than does the longer allele
(A2) [14]. Thus, our hypothesis could be tested for the
selected group of cases (heterozygotes A1/A2). In these
cases, the mutation of the allele allowing for the higherTP53 expression overrides the normal TP53 activity
(through definite predominance of the mutated mRNA)
despite the retention of the wild-type allele at the DNA
level (haploinsufficiency). This lead to the aim of this
study – to investigate if PIN3 polymorphism play a role
in TP53 haploinsufficiency. Undoubtedly, behind the
haploinsufficiency phenomenon there is an unidenti-
fied mechanism, which probably modulates TP53 mRNA
expression.Methods
Material
The study included human cancer cell lines, cultured
cells and tumor samples. The commercially available
human cell lines were obtained from American Type
Culture Collection (ATCC, Manassas, USA – SW962) and
from Stratagene (California, USA – AD293). For this
study the TP53 sequencing results from more than 250
tumor samples were analyzed. We have reviewed the se-
quencing results for 307 samples (partially previously pub-
lished [2,3,19,20], partially performed specifically for this
analysis). Since a portion of the archival material was no
longer available, PIN3 and codon 72 analysis was possible
in 250 cases, among which there were 45 cases with mis-
sense mutations (Table 1), which were subjected to further
analysis. All samples were collected using the protocols
approved by the Bioethical Committee of the Medical
University of Lodz (Approval No. RNN/9/10/KE and No.
RNN/53/08/KE). Written informed consent was obtained
from all patients and their data were processed and stored
according to the principles expressed in the Declaration of
Helsinki.Cell culture
Cells were cultured in MEM or DMEM supplemented with
10% FBS (PAA, Linz, Austria) and antibiotics (penicillin/
streptomycin/gentamicin; GIBCO, BRL, Paisley, Great
Britain) in 5% CO2. Adherent cells were passaged with
trypsin (GIBCO) before obtaining 70% confluence.DNA and RNA isolation
Total DNA and RNA were isolated from cell cultures
and frozen tumor fragments (stored at −80°C) and periph-
eral blood leukocytes obtained from patients and healthy
volunteers. The isolation was performed using AllPrep
DNA/RNA Mini Kit (Qiagen, Hilden, Germany) ac-
cording to the manufacturer's protocol. During RNA
isolation DNase was used. Nucleic acid concentration
was determined spectrophotometrically. 100 ng of total
RNA was reverse transcribed into single-stranded cDNA
using QuantiTect Rev. Transcription Kit (Qiagen) accord-
ing to the manufacturer’s protocol.
Table 1 Results of DNA and cDNA sequencing analysis in samples with TP53 mutations [2,3,19,20]




TP53 mutations; cases showing discrepancies between cDNA and DNA
1 Glioblastoma MT1 175; CGC > CAC; Arg > His MT1 >MT2 MT1 = MT2 A1/A2 C/G
MT2 282; CGG > TGG; Arg > Trp
2 Glioblastoma 237; ATG > ATA; Met > Ile MT WT >MT A1/A2 C/G
3 Glioblastoma 273; CGT > CAT; Arg > His MT WT >MT A1 C
4 Glioblastoma 234; TAC > CAC; Tyr > His MT WT >MT A1 G
5 Glioblastoma 273; CGT > TGT; Arg > Cys MT WT >MT A1 G
6 Glioblastoma 190; CCT > TCT; Pro > Ser MT WT =MT A1 G
7 Glioblastoma 152; CCG > CTG; Pro > Leu MT WT =MT A2 C
8 Glioblastoma 273; CGT > TGT; Arg > Cys MT WT =MT A2 G
9 Glioblastoma 237; ATG > ATA; Met > Ile MT MT >WT A1 C
10 Glioblastoma 161; GCC > ACC; Ala > Thr MT MT >WT A2 C/G
11 Soft tissue sarcoma 248; CGG > CAG; Arg > Gln MT WT A1 G
12 Soft tissue sarcoma 273; CGT > TGT; Arg > Cys MT WT =MT A1 G
13 Soft tissue sarcoma 216; GTG > ATG; Val > Met MT MT >WT A1/A2 C/G
14 Colorectal cancer 173; GTG > ATG; Val > Met MT MT >WT A1 G
15 Colorectal cancer 248; CGG > TGG; Arg > Trp MT WT A1 C/G
16 Colorectal cancer 175; CGC > CAC; Arg > His MT WT =MT A1 G
17 Colorectal cancer 273; CGT > CAT; Arg > His MT >WT WT =MT A1 G
18 Colorectal cancer 285; GAG > AAG; Glu > Lys MT >WT WT A1 G
19 Colorectal cancer 245; GGC > AGC; Gly > Ser MT WT >MT A2 C
20 Colorectal cancer 248; CGG > CAG; Arg > Gln MT WT >MT A1/A2 C/G
21 Colorectal cancer 273; CGT > CAT; Arg > His MT >WT WT >MT A1/A2 C/G
22 Colorectal cancer 282; CGG > TGG; Arg > Trp MT WT >MT A1 G
23 Colorectal cancer 245; GGC > AGC; Gly > Ser MT =WT WT >MT A1 G
24 Colorectal cancer 216; GTG > ATG; Val > Met MT >WT WT =MT A1 G
25 Colorectal cancer 245; GGC > AGC; Gly > Ser MT =WT WT >MT A1 G
26 Colorectal cancer 175; CGC > CAC; Arg > His MT WT =MT A1 G
27 Colorectal cancer 175; CGC > CAC; Arg > His MT MT >WT A2 C/G
28 Leukemia (AML) 216; GTG > ATG; Val > Met MT WT A1 C/G
29 Leukemia (AML) 267; CGG > GGG; Arg > Gly MT =WT WT A1 C/G
30 Prostate cancer 239; AAC > GAC; Asn > Asp MT WT =MT A1/A2 C/G
TP53 mutations; no discrepancies between DNA and cDNA sequencing
31 Glioblastoma 214; AGT > AAT; Ser > Asn WT =MT WT =MT A1 G
32 Glioblastoma 282; CGG > TGG; Arg > Trp WT =MT WT =MT A1 G
33 Astrocytoma 179; CAT > GAT; His > Asp WT =MT WT =MT A1 C/G
34 Glioblastoma 267; CGG > TGG; Pro > Trp WT =MT WT =MT A1 C/G
35 Glioblastoma 173; GTG > TTG; Val > Leu WT =MT WT =MT A1 G
36 Glioblastoma 273; CGT > TGT; Arg > Cys WT = MT WT =MT A1 G
37 Glioblastoma 190; CCT > CTT; Pro > Leu WT =MT WT =MT A2 C
38 Glioblastoma 145; CTG > CAG; Leu > Gln MT MT A1 C
39 Soft tissue sarcoma 273; CGT > TGT; Arg > Cys WT = MT WT =MT A1 G
40 Soft tissue sarcoma 215; AGT > AAA; Ser > Lys MT >WT MT >WT A1 C/G
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Table 1 Results of DNA and cDNA sequencing analysis in samples with TP53 mutations [2,3,19,20] (Continued)
41 Soft tissue sarcoma 248; CGG > CAG; Arg > Gln MT MT A1 G
42 Soft tissue sarcoma 173; GTG > TTG; Val > Leu MT MT A1/A2 C/G
43 Colorectal cancer 273; CGT > CAT; Arg > His WT = MT WT =MT A1 C
44 Colorectal cancer 134; TTT > CTT; Phe > Leu WT =MT WT =MT A1 C/G
45 Colorectal cancer 175; CGC > CAC; Arg > His WT = MT WT =MT A1 C/G
AML – acute myeloid leukemia; WT – wild-type template; MT – mutated template; A1, A2 – polymorphic variants of PIN3; C – cytosine; G – guanine.
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Exons 4 – 8 of TP53 were sequenced in search of muta-
tions. The primers used for the PCR amplification of TP53
DNA and cDNA sequences and sequencing primers
are listed in tables A1 and A2 (Additional file 1). TP53
sequencing was performed using BigDye Seq kit v3.1
(Applied Biosystems, Foster City, CA, USA). The sequences
were analyzed with the ABI 3130 genetic analyzer and
DNA Sequencing Analysis Software (Applied Biosystems).
Bacterial subcloning of a DNA fragment containing the
TP53 codon 72 and PIN3 from samples with a single
heterozygous mutation
Bacterial subcloning was performed in order to deter-
mine which allele (A1 or A2) is preferentially mutated in
samples with a heterozygous TP53 mutation. Since PIN3
is an intronic polymorphism, it may only be analyzed at
the DNA level. Therefore, a direct analysis would require
the subcloning of about 3 thousand nucleotide-long se-
quence (the distance between intron 3 and exon 8) into
bacterial vectors. To avoid the technical inconveniences
we performed an indirect analysis using another poly-
morphic site at codon 72 (Figure 1). Such an analysis was
only possible for the samples with heterozygous TP53Figure 1 A schematic diagram of the subcloning procedure. A. Sequen
which allele with cytosine or guanine in codon 72 (exon 4) is mutated with
codon 72 heterozygosity were subjected to bacterial subcloning. A fragme
samples were cloned into a bacterial vector and sequenced. Such an analy
for the detection of haplotypes (i.e. which codon 72 variant co-localized wi
which PIN3 allele (A1 or A2) is the mutated one.mutation, PIN3 A1/A2 heterozygosity, codon 72 C/G
heterozygosity and predominance of the mutated template
during the cDNA sequencing. Firstly, cDNA sequencing
of exons 4 – 8 was used to determine which allele (at
codon 72) is mutated (Figure 2), since the predominance
of the mutated allele would be also observed here. Subse-
quently, the bacterial subcloning of DNA fragments con-
taining intron 3 and exon 4 (and thus, both polymorphic
sites) from samples with a single heterozygous mutation
was performed. It allowed for the sequencing of each allele
separately, and therefore, for the detection of haplotypes
(i.e. which codon 72 variant co-localized with which PIN3
variant). From these observations it may be easily inferred
which PIN3 variant was mutated; e.g. if cDNA analysis re-
vealed that the mutation co-localized with cytosine in
codon 72 and subcloning showed that codon 72 cytosine
co-localized with the longer PIN3 variant, we may con-
clude that the mutation occurred within the allele with A2
PIN3 variant. As the vector for cloning pUC19 plasmid
was used. The TP53 DNA fragment was amplified by PCR
using the primers complementary to the target DNA with
additional nucleotides at the 5’ ends to facilitate digestion
(Table A3, Additional file 1). Both the PCR product and the
vector were digested with restriction enzymes BamHI andcing of TP53 cDNA fragment containing exons 4 – 8, that specify
in exons 5 – 8. B. The samples containing an exonic mutation and
nt of TP53 gene comprising intron 3 and codon 72 from the selected
sis allowed for the sequencing of each allele separately, and therefore,
th which PIN3 variant). C. Combination of these results allows to infer
Figure 2 The result of capillary sequencing of the TP53 exon 8 fragment with the designated R273C mutation (the line marks the
mutated nucleotide).
Winiecka-Klimek et al. BMC Cancer 2014, 14:669 Page 5 of 11
http://www.biomedcentral.com/1471-2407/14/669HindIII (Fermentas, Thermo Fisher Scientific, Waltham,
USA) in two separate reactions according to the manufac-
turer's protocol. 1-sample proportion test with continuity
correction was used to assess the probability of the ob-
served allele distribution.
Plasmids construction
Generation of the reporter assay plasmids was performed
by inserting DNA fragments comprising the intron 3
sequence of the TP53 gene, obtained with PCR on the
heterozygous template. The PCR products were sepa-
rated with 2% agarose gel electrophoresis and DNA
was extracted from the gel using AxyPrep DNA Gel
Extraction Kit (Axygen, Corning, New York, USA).
The fragments of 174 and 190 bp were chosen for in-
sertion into pTKLuc + reporter plasmid (ATCC). Both
the plasmid and the inserts with the sequence of inter-
est were digested with BamHI and HindIII restriction
enzymes (New England Biolabs, NEB, Ipswich, USA) in
two separate reactions according to the manufacturer's
protocol. The products were purified by QIAquick
PCR Purification Kit (Qiagen) and ligated for 30 min
with T4Quick Ligase (NEB) according to the manufac-
turer’s protocol. The ligation products were used for
the transformation of E. coli NEB Turbo competent
cells (NEB). The plasmids from the selected clones were
sequenced to distinguish different polymorphic variants
(construct A1 from construct A2) and to confirm the cor-
rect insertion of both constructs.
Dual luciferase reporter assay
Two cell lines with different characteristics were used
for the transfection and the subsequent dual luciferase
reporter assay: AD293 and SW962. AD293 (which is com-
monly used for dual luciferase reporter assays [21,22]),contained only wild-type TP53 and constituted the normal
sample. SW962 was chosen as a cell line with heterozy-
gous mutation of TP53. For the reporter assay cells were
seeded in 6-well plates (2.5x105 cells/well) 24 h prior to
the transfection. Cells were cotransfected with 0.25 μg of
specific pTKLuc + reporter plasmid (ATCC; containing
Firefly luciferase and either A1, A2 or no insert) and
0.25 μg of pGL4.74 control vector (containing Renilla
luciferase; Promega, Madison, USA) using Lipofectamine
Plus Reagent (Invitrogen, Carlsbad, USA) in OptiMEM
(GIBCO) without antibiotics. 24 h posttransfection the
cells were lysed using Passive Lysis Buffer (Promega). The
lysates were analyzed by measurement of luciferase activ-
ity (Firefly and Renilla) using Dual-Luciferase Reporter
Assay System (Promega) according to the manufacturer’s
protocol on TD20/20 Luminometer (Promega). For AD293
cell line – 11 and for SW962 cell line – 8 independent ex-
periments were performed. The ratios of luciferase activity
were normalized (Fluc value/Rluc value). The ratios for
the constructs were subsequently normalized to the
control samples (C, transfected with the plasmid without
inserts). The results are presented as mean ratios from in-
dependent experiments for each cell line, compared to
mean ratio obtained for the control sample (Table A4,
Additional file 1). The statistical analysis was performed
using Mann–Whitney U-test.
Bioinformatic analysis
The sequence of TP53 intron 3, potentially capable of
forming G-quadruplex structure, was obtained from IARC
TP53 Database (Table A5, see Additional file 1) [23]. To
predict the secondary DNA structure of TP53 intron
3, RNAfold from ViennaRNA package version 2.1.6 with
DNA energy parameters was used [24]. The RNA-
fold predicts secondary DNA structure through energy
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fault minimum free energy algorithm which yields the sin-
gle optimal structure was used.
Results
TP53 DNA and cDNA sequencing
Among the 307 samples there were 97 gliomas, 94 soft
tissue sarcomas, 31 colorectal cancers, 20 prostate can-
cers, 23 acute myeloid leukemias and 42 invasive
breast duct carcinomas. Alterations of the TP53 gene
were detected in 64 (20.8%) tumors (Table A6, see
Additional file 1); a high number of TP53 mutated
samples were found in colorectal cancer (19/31; 61.3%)
and in glioma (25/97; 25.8%). TP53 mutations were
also detected in 19% (8/42) of invasive breast duct car-
cinoma, 9.6% of soft tissue sarcoma (9/94), 8.7% of
acute myeloid leukemia (2/23) and 5% of prostate can-
cer cases (1/20). For further analyses the 45 cases with
missense mutations were used (Table 1). Within this
group 15 showed consistent results of DNA and cDNA
sequencing, while 30 cases showed differences between
them (Table 1).
PIN3 polymorphism analysis for cases with TP53 mutation
PIN3 polymorphism status was identified with sequen-
cing (Table 1). Among the cases with a TP53 mutation
and no differences between DNA and cDNA, 13 were
recognized as A1/A1 homozygotes, 1 as A2/A2 homozy-
gote and 1 as heterozygote. On the other hand, among the
cases with differences between DNA and cDNA, there
were 19 A1/A1 homozygotes, 5 A2/A2 homozygotes and
6 heterozygotes, which constituted the starting point for
further analysis aiming to determine the haplotype of the
tested alterations.
Bacterial subcloning of a DNA fragment containing the
TP53 codon 72 and PIN3 from samples with a single
heterozygous mutation
The sequencing of the obtained clones revealed that the
mutation co-localized with the longer PIN3 variant (A2)
in all six cases (p = 0.04) (Table 2) as well as with cyto-
sine at codon 72 (in 5 out of 6 cases), both of which are
the less common variants [13,14].
Dual luciferase assay
Genetic reporter assay confirmed that in all samples the
transfection with construct A2 resulted in the higher lucif-
erase expression than did the transfection with construct
A1 (Figure 3; Table A4, Additional file 1). The difference
between the luciferase activity of the control sample and
A1 variant was marginal and not statistically significant
(A1/C = 1.32; p = 0.056 for AD293; A1/C = 0.98; p = 0.645
for SW962), while samples transfected with A2 variant
showed significantly higher luciferase activity than thecontrol sample (A2/C =1.53; p = 0.008 for AD293; A2/
C = 1.59; p = 0.001 for SW962). A2/A1 ratio ranged
from 1.16 for AD293 (p = 0.019) to 1.59 for SW962
(p = 0.0019). The collective analysis for both cell lines
proved the significance of the differences between the two
variants (p = 0.00019). Normalized luciferase activities
(Fluc/Rluc value) from independent experiments for each
construct (A1 or A2) compared to normalized luciferase
activities obtained for control sample are presented in
Figure 3A. Graphs illustrate also comparison of ratios of
A2 to A1 for each cell line separately and for both cell
lines (Figure 3B).
Bioinformatic analysis
The results of A1 and A2 TP53 intron 3 secondary
structure predictions are shown in Table A7 (Additional
file 1). According to our analyses, both structures with
G-quadruplex (Figure 4 and Figure 5) have lower free
energy than the respective canonical structures (Figure 6
and Figure 7), thus, the G-quadruplex structure would
be preferred. However, the differences in free energy
between the canonical structures of both polymorphic
variants are significantly higher than between the respect-
ive G-quadruplexes. Finally, the predicted free energy is
lower for the longer variant (A2) in both structures
(canonical or G-quadruplex), which may account for
its greater in vivo stability.
Discussion
The differences in the sequencing of TP53 between DNA
and cDNA (mRNA) may result from the nonequivalence
of the alleles’ impact on expression due to specific poly-
morphisms or epigenetic changes [14]. To investigate the
hypothetical role of PIN3 polymorphism in TP53 expres-
sion, we compared the frequencies of both polymorphic
variants between the cases with and without the men-
tioned differences. Secondly, we analyzed which PIN3
variant is the mutated one in cases showing such discrep-
ancies and conducted a reporter assay to compare the
expression levels of both variants. Finally, we performed a
bioinformatic analysis of the stability of both alleles
with respect to their potential structures (canonical or
G-quadruplex). The mutational analysis showed that
among the 45 cases with a TP53 mutation, the majority
exhibited differences between DNA and cDNA sequencing
(66.7%). The group without such discrepancies consisted
mostly of A1/A1 homozygotes (86.7%), of one A2/A2
homozygote and one heterozygote. The other group also
comprised mainly A1/A1 homozygotes (63.3%), but the
frequency of heterozygotes was higher (6 cases – 20.0%)
and there were 5 cases of A2/A2 homozygotes (16.7%).
Such a distribution suggests a relation of the longer
variant with the differences between the expression of
both alleles. Since the appropriate PIN3 analysis required
Table 2 Results of DNA and cDNA sequencing combined with the results of bacterial subcloning analyses
Number
of sample





Type cDNA DNA Colonies PIN3 Codon 72 Conclusions






2 Glioblastoma 237; ATG > ATA
Met > Ile
MT WT >MT A1/A2 C/G C L2-2 A1 G A2 MT
13 Soft tissue
sarcoma
216; GTG > ATG
Val >Met
MT MT >WT A1/A2 C/G C L3-1L3-2 A2 C A2 MT
20 Colorectal cancer 248; CGG> CAG
Arg >Gln
MT WT >MT A1/A2 C/G G L4-2 A1 C A2 MT
21 Colorectal cancer 273; CGT > CAT
Arg > His
MT >WT WT >MT A1/A2 C/G C L5-1L5-2 A2 C A2 MT
30 Prostate cancer 239; AAC >
GAC Asn > Asp
MT MT =WT A1/A2 C/G C L6-2 A2 C A2 MT
MT – mutated template; WT – wild-type template; A1, A2 - polymorphic variants of PIN3; C – cytosine; G – guanine.
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heterozygosity and DNA/cDNA differences), it could
be performed in only 6 out of 250 tumor cases. In all
A1/A2 heterozygotes with the discussed DNA/cDNA
differences the longer variant (A2) was the mutated
one. This observation may support the hypothesis that
mutations within the allele demonstrating a higher ex-
pression result in the differences in the sequencing
patterns. Conversely, Gemignani et al. showed that the
shorter allele (A1) should be related to the higherFigure 3 Luciferase activity in cells transfected with control, A1 and A
luciferase activity depending on cell line and transfecting construct. B. Norexpression of TP53 [14], however, their analyses were
based on immortalized normal lymphocyte cells, known
to present domains of monoallelic expression, which are
possibly artifactual [26], and which may insufficiently re-
flect the conditions within tumor cells irrespective of the
cell origin [14]. The TP53 gene is most frequently mutated
in solid tumors [27] – the highest percentage of mutations
in this study was detected in colorectal cancer (19/31;
61.3%) and glioma (25/97; 25.8%), in hematological malig-
nancies these mutations are less frequent (in this study2 constructs (* p < 0,05; ** p < 0,01; *** p < 0,001). A. Normalized
























































Figure 4 TP53 intron 3 (A1) secondary structure prediction (in G-quadruplex prediction mode).
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were mutated), but often strongly correlated with unfavor-
able prognosis and resistance to therapy [28,29].
Next, we performed a dual luciferase reporter analysis
to test the hypothetical influence of specific PIN3 variants
on TP53 expression. Its results support the association







































Figure 5 TP53 intron 3 with 16 bp duplication (A2) secondary structucomparison to the A1 variant. This observation is espe-
cially important in the light of the TP53 tetramer
structure, whose proper function is possible only with
all wild-type subunits [30], therefore the increased ex-
pression of the mutated allele will further abolish the
activity of the wild-type TP53. PIN3 may be a potential



















































































































































































































Figure 7 TP53 intron 3 with 16 bp duplication (A2) secondary structure prediction (in canonical structure prediction mode).
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may only apply to a minority of cases showing TP53 hap-
loinsufficiency, as the frequency of PIN3 heterozygosity is
estimated as 20% in European population [14], 25% in
South America and 31% in Asia [31,32]. As reported in
several case–control studies, PIN3 A2 allele is associated
with an increased risk of various cancer types, particularly
in colorectal and breast cancer (only in heterozygotes in
case of the latter) [13-15,33].
Finally, we took a closer look at the sequence of intron
3. It has a relatively small size (of 93 bp), therefore, the
additional 16 bp insertion leads to an increase of intron
length by 17%. Such change can lead to alteration in
protein function or gene expression [12,16-18]. Further-
more, the duplicated fragment consists of series of three
or four guanines which are potentially able to form
secondary structures – G-quadruplexes. Such structures
within intron 3 of TP53 pre-mRNA were confirmed by
Marcel et al. [12]. G-quadruplexes on DNA strands
function as regulators of replication and transcription.
These motifs are especially common in the regions up-
stream of transcription start site of regulatory genes or
oncogenes, while rarely within tumor suppressor genes
[34], which advocates for the significance of PIN3. Since
the duplication both significantly increases the intron's
length and contains additional G-tracts, it most prob-
ably affects the topology of the G-quadruplexes and its
stability, which, in turn, may have an impact on the
transcript and, subsequently, on TP53 expression level.
G-quadruplexes within pre-mRNA have already been
confirmed [12], therefore, it was necessary to inquire
whether such structures can be formed within DNA. A
preliminary bioinformatic analysis showed that both
DNA variants are capable of forming G-quadruplexes,
however, with varied stability. The predicted free energy
of the longer variant (A2) was lower, therefore, the G-
quadruplex structure would be more stable (Table A7).
The impact of G-quadruplex on transcription depends
on its location. G-quadruplex structures within the tem-
plate strand inhibit transcription, whereas those within the
non-template strand enhance the process [35]. G-tracts can
also participate in hybrid quadruplexes (HQ) formation,
which are intermolecular forms of G-quadruplexes formed
between non-template DNA and nascent mRNA [36]. Un-
doubtedly, the HQ structures require more attention due
to their significant role in the regulation of transcription,
both in vitro and in vivo [36].
Conclusions
The presented data strongly suggest that the TP53 allele
with PIN3 duplication shows higher expression of TP53
mRNA in comparison to the allele without the duplication.
A single mutation of the allele with PIN3 duplication in
PIN3 heterozygotes (A1/A2) might be partially responsiblefor TP53 haploinsufficiency. These findings may provide a
new insight into the search for the unknown haploinsuffi-
ciency mechanism and further therapeutic applications.
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